MAMisol Ahn

Misol Ahn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Misol Ahn has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Ethan A. Merritt

    Contribution from the Biomolecular Structure Center and Departments of Biochemistry and Biological Structure, University of Washington, Seattle, Washington 98195, and Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, Maryland 20815

    4 shared publications
  • Stephen J. DeArmond

    From the Department of Pathology (MA, AO, SJD) and Institute for Neurodegenerative Diseases (MA, SJD), University of California San Francisco, California; Department of Pharmacology, University of Washington, Seattle, Washington (FK); and McLaughlin Research Institute, Great Falls, Montana (RP, GC)

    4 shared publications
  • Abby Oehler

    From the Department of Pathology (MA, AO, SJD) and Institute for Neurodegenerative Diseases (MA, SJD), University of California San Francisco, California; Department of Pharmacology, University of Washington, Seattle, Washington (FK); and McLaughlin Research Institute, Great Falls, Montana (RP, GC)

    3 shared publications
  • Erkang Fan

    Contribution from the Biomolecular Structure Center and Departments of Biochemistry and Biological Structure, University of Washington, Seattle, Washington 98195, and Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, Maryland 20815

    3 shared publications
  • Jason C. Pickens

    Contribution from Department of Biochemistry, Department of Biological Structure, Biomolecular Structure Center, Department of Chemistry, and Howard Hughes Medical Institute, University of Washington, Box 357742, Seattle, Washington 98195

    3 shared publications
  • Sina Ghaemmaghami

    University of Rochester

    3 shared publications

Latest Publications

  • Brain Aggregates: An EffectiveIn VitroCell Culture System Modeling Neurodegenerative Diseases

    by Misol Ahn, Franck Kalume, Rose Pitstick, Abby Oehler, George Carlson, Stephen J. DeArmond

    Drug discovery for neurodegenerative diseases is particularly challenging because of the discrepancies in drug effects between in vitro and in vivo studies. These discrepancies occur in part because current cell culture systems used for drug screening have many limitations. First, few cell culture systems accurately model human aging or neurodegenerative diseases. Second, drug efficacy may differ between dividing and stationary cells, the latter resembling nondividing neurons in the CNS. Brain aggregates (BrnAggs) derived from embryonic day 15 gestation mouse embryos may represent neuropathogenic processes in prion disease and reflect in vivo drug efficacy. Here, we report a new method for the production of BrnAggs suitable for drug screening and suggest that BrnAggs can model additional neurological diseases such as tauopathies. We also report a functional assay with BrnAggs by measuring electrophysiological activities. Our data suggest that BrnAggs could serve as an effective in vitro cell culture system for drug discovery for neurodegenerative diseases.


  • Open Access

    Convection-Enhanced Delivery of AAV2-PrPshRNA in Prion-Infected Mice

    by Misol Ahn, Krystyna Bajsarowicz, Abby Oehler, Azucena Lemus, Krystof Bankiewicz, Stephen J. DeArmond

    Prion disease is caused by a single pathogenic protein (PrPSc), an abnormal conformer of the normal cellular prion protein PrPC. Depletion of PrPC in prion knockout mice makes them resistant to prion disease. Thus, gene silencing of the Prnp gene is a promising effective therapeutic approach. Here, we examined adeno-associated virus vector type 2 encoding a short hairpin RNA targeting Prnp mRNA (AAV2-PrP-shRNA) to suppress PrPC expression both in vitro and in vivo. AAV2-PrP-shRNA treatment suppressed PrP levels and prevented dendritic degeneration in RML-infected brain aggregate cultures. Infusion of AAV2-PrP-shRNA-eGFP into the thalamus of CD-1 mice showed that eGFP was transported to the cerebral cortex via anterograde transport and the overall PrPC levels were reduced by ∼70% within 4 weeks. For therapeutic purposes, we treated RML-infected CD-1 mice with AAV2-PrP-shRNA beginning at 50 days post inoculation. Although AAV2-PrP-shRNA focally suppressed PrPSc formation in the thalamic infusion site by ∼75%, it did not suppress PrPSc formation efficiently in other regions of the brain. Survival of mice was not extended compared to the untreated controls. Global suppression of PrPC in the brain is required for successful therapy of prion diseases.


  • Open Access

    Levels of the Mahogunin Ring Finger 1 E3 Ubiquitin Ligase Do Not Influence Prion Disease

    by Derek Silvius, Rose Pitstick, Misol Ahn, Delisha Meishery, Abby Oehler, Gregory S. Barsh, Stephen J. DeArmond, George A. Carlson, Teresa M. Gunn

    Prion diseases are rare but invariably fatal neurodegenerative disorders. They are associated with spongiform encephalopathy, a histopathology characterized by the presence of large, membrane-bound vacuolar structures in the neuropil of the brain. While the primary cause is recognized as conversion of the normal form of prion protein (PrPC) to a conformationally distinct, pathogenic form (PrPSc), the cellular pathways and mechanisms that lead to spongiform change, neuronal dysfunction and death are not known. Mice lacking the Mahogunin Ring Finger 1 (MGRN1) E3 ubiquitin ligase develop spongiform encephalopathy by 9 months of age but do not become ill. In cell culture, PrP aberrantly present in the cytosol was reported to interact with and sequester MGRN1. This caused endo-lysosomal trafficking defects similar to those observed when Mgrn1 expression is knocked down, implicating disrupted MGRN1-dependent trafficking in the pathogenesis of prion disease. As these defects were rescued by over-expression of MGRN1, we investigated whether reduced or elevated Mgrn1 expression influences the onset, progression or pathology of disease in mice inoculated with PrPSc. No differences were observed, indicating that disruption of MGRN1-dependent pathways does not play a significant role in the pathogenesis of transmissible spongiform encephalopathy.


  • Open Access

    Pharmacokinetics of Quinacrine Efflux from Mouse Brain via the P-glycoprotein Efflux Transporter

    by Misol Ahn, Sina Ghaemmaghami, Yong Huang, Puay-Wah Phuan, Barnaby C. H. May, Kurt Giles, Stephen J. DeArmond, Stanley B. Prusiner

    The lipophilic cationic compound quinacrine has been used as an antimalarial drug for over 75 years but its pharmacokinetic profile is limited. Here, we report on the pharmacokinetic properties of quinacrine in mice. Following an oral dose of 40 mg/kg/day for 30 days, quinacrine concentration in the brain of wild-type mice was maintained at a concentration of ∼1 µM. As a substrate of the P-glycoprotein (P-gp) efflux transporter, quinacrine is actively exported from the brain, preventing its accumulation to levels that may show efficacy in some disease models. In the brains of P-gp–deficient Mdr10/0 mice, we found quinacrine reached concentrations of ∼80 µM without any signs of acute toxicity. Additionally, we examined the distribution and metabolism of quinacrine in the wild-type and Mdr10/0 brains. In wild-type mice, the co-administration of cyclosporin A, a known P-gp inhibitor, resulted in a 6-fold increase in the accumulation of quinacrine in the brain. Our findings argue that the inhibition of the P-gp efflux transporter should improve the poor pharmacokinetic properties of quinacrine in the CNS.


  • A Brain Aggregate Model Gives New Insights Into the Pathobiology and Treatment of Prion Diseases

    by Krystyna Bajsarowicz, Misol Ahn, Larry Ackerman, Bernadette N. DeArmond, George Carlson, Stephen J. DeArmond

    Brain aggregates (BrnAggs) derived from fetal mouse brains contain mature neurons and glial cells. We determined that BrnAggs are consistently infected with Rocky Mountain Laboratory scrapie strain prions and produce increasing levels of the pathogenic form of the prion protein (PrPSc). Their abundant dendrites undergo degeneration shortly after prion infection. Treatment of prion-infected BrnAggs with drugs, such as a γ-secretase inhibitors and quinacrine (Qa), which stop PrPSc formation and dendritic degeneration, mirrors the results from rodent studies. Because PrPSc is trafficked into lysosomes by en-docytosis and autophagosomes by phagocytosis in neurons of prion strain-infected BrnAggs, we studied the effects of drugs that modulate subcellular trafficking. Rapamycin (Rap), which activates autophagy, markedly increased light-chain 3-II (LC3-II)-positive autophago-somes and cathepsin D-positive lysosomes in BrnAggs but could not eliminate the intracellular PrPSc within them. Adding Qa to Rap markedly reduced the number of LC3-II-positive autolysosomes. Rap + Qa created a competition between Rap increasing and Qa decreasing LC3-II. Rapamycin + Qa decreased total PrPSc by 56% compared with that of Qa alone, which reduced PrPSc by 37% relative to Rap alone. We conclude that the decrease was dominated by the ability of Qa to decrease the formation of PrPSc. Therefore, BrnAggs provide an efficient in vitro tool for screening drug therapies and studying the complex biology of prions.


  • Open Access

    Chemical Induction of Misfolded Prion Protein Conformers in Cell Culture

    by Sina Ghaemmaghami, Julie Ullman, Misol Ahn, Susan St. Martin, Stanley B. Prusiner


  • Open Access

    Continuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions

    by Sina Ghaemmaghami, Misol Ahn, Pierre Lessard, Kurt Giles, Giuseppe Legname, Stephen J. DeArmond, Stanley B. Prusiner

    Quinacrine is a potent antiprion compound in cell culture models of prion disease but has failed to show efficacy in animal bioassays and human clinical trials. Previous studies demonstrated that quinacrine inefficiently penetrates the blood-brain barrier (BBB), which could contribute to its lack of efficacy in vivo. As quinacrine is known to be a substrate for P-glycoprotein multi-drug resistance (MDR) transporters, we circumvented its poor BBB permeability by utilizing MDR0/0 mice that are deficient in mdr1a and mdr1b genes. Mice treated with 40 mg/kg/day of quinacrine accumulated up to 100 µM of quinacrine in their brains without acute toxicity. PrPSc levels in the brains of prion-inoculated MDR0/0 mice diminished upon the initiation of quinacrine treatment. However, this reduction was transient and PrPSc levels recovered despite the continuous administration of quinacrine. Treatment with quinacrine did not prolong the survival times of prion-inoculated, wild-type or MDR0/0 mice compared to untreated mice. A similar phenomenon was observed in cultured differentiated prion-infected neuroblastoma cells: PrPSc levels initially decreased after quinacrine treatment then rapidly recovered after 3 d of continuous treatment. Biochemical characterization of PrPSc that persisted in the brains of quinacrine-treated mice had a lower conformational stability and different immunoaffinities compared to that found in the brains of untreated controls. These physical properties were not maintained upon passage in MDR0/0 mice. From these data, we propose that quinacrine eliminates a specific subset of PrPSc conformers, resulting in the survival of drug-resistant prion conformations. Transient accumulation of this drug-resistant prion population provides a possible explanation for the lack of in vivo efficacy of quinacrine and other antiprion drugs. Prion diseases belong to the class of neurodegenerative disorders that include Alzheimer, Parkinson and Huntington diseases. In each of these disorders, a specific protein in the brain changes shape and accumulates, leading to neuronal loss and damage. These diseases are uniformly fatal after a period of neurodegeneration, dementia and motor dysfunction. Quinacrine, an antimalarial drug, is able to eliminate prions from dividing cells in culture, yet is ineffective in diseased mice and human patients. Here, we provide an explanation for this failure. Our data indicate that the administration of quinacrine results in the proliferation of drug-resistant prions. This insight will enable us to develop more effective antiprion therapeutics in the future.


  • Open Access

    Regulation of NaV1.2 Channels by Brain-Derived Neurotrophic Factor, TrkB, and Associated Fyn Kinase

    by Misol Ahn, Daniel Beacham, Ruth E. Westenbroek, Todd Scheuer, William A. Catterall

    Voltage-gated sodium channels are responsible for action potential initiation and propagation in neurons, and modulation of their function has an important impact on neuronal excitability. Sodium channels are regulated by a Src-family tyrosine kinase pathway, and this modulation can be reversed by specifically bound receptor phosphoprotein tyrosine phosphatase-β. However, the specific tyrosine kinase and signaling pathway are unknown. We found that the sodium channels in rat brain interact with Fyn, one of four Src-family tyrosine kinases expressed in the brain. NaV1.2 channels and Fyn are localized together in the axons of cultured hippocampal neurons, the mossy fibers of the hippocampus, and cell bodies, dendrites, and axons of neurons in many other brain areas, and they coimmunoprecipitate with Fyn from cotransfected tsA-201 cells. Coexpression of Fyn with NaV1.2 channels decreases sodium currents by increasing the rate of inactivation and causing a negative shift in the voltage dependence of inactivation. Reconstitution of a signaling pathway from brain-derived neurotrophic factor (BDNF) to sodium channels via the tyrosine receptor kinase B (TrkB)/p75 neurotrophin receptor and Fyn kinase in transfected cells resulted in an increased rate of inactivation of sodium channels and a negative shift in the voltage dependence of inactivation after treatment with BDNF. These results indicate that Fyn kinase is associated with sodium channels in brain neurons and can modulate NaV1.2 channels by tyrosine phosphorylation after activation of TrkB/p75 signaling by BDNF.


  • Open Access

    Sites and Molecular Mechanisms of Modulation of NaV1.2 Channels by Fyn Tyrosine Kinase

    by Daniel Beacham, Misol Ahn, William A. Catterall, Todd Scheuer

    Voltage-gated sodium channels are important targets for modulation of electrical excitability by neurotransmitters and neurotrophins acting through protein phosphorylation. Fast inactivation of NaV1.2 channels is regulated via tyrosine phosphorylation by Fyn kinase and dephosphorylation by receptor phosphoprotein tyrosine phosphatase-β, which are associated in a signaling complex. Here we have identified the amino acid residues on NaV1.2 channels that coordinate binding of Fyn kinase and mediate inhibition of sodium currents by enhancing fast inactivation. Fyn kinase binds to a Src homology 3 (SH3)-binding motif in the second half of the intracellular loop connecting domains I and II (LI–II) of NaV1.2, and mutation of that SH3-binding motif prevents Fyn binding and Fyn enhancement of fast inactivation of sodium currents. Analysis of tyrosine phosphorylation sites by mutagenesis and functional expression revealed a multisite regulatory mechanism. Y66 and Y1893, which are in consensus sequences appropriate for binding to the Fyn SH2 domain after phosphorylation, are both required for optimal binding and regulation by Fyn. Y730, which is located near the SH3-binding motif in LI–II, and Y1497 and Y1498 in the inactivation gate in LIII–IV, are also required for optimal regulation. Phosphorylation of these sites likely promotes fast inactivation. Fast inactivation of the closely related NaV1.1 channels is not modulated by Fyn, and these channels do not contain an SH3-binding motif in LI–II. Subtype-selective modulation by tyrosine phosphorylation/dephosphorylation provides a mechanism for differential regulation of sodium channels by neurotrophins and tyrosine phosphorylation in unmyelinated axons and dendrites, where NaV1.2 channels are expressed in brain neurons.


  • Solution and Crystallographic Studies of Branched Multivalent Ligands that Inhibit the Receptor-Binding of Cholera Toxin

    by Zhongsheng Zhang, Ethan A. Merritt, Misol Ahn, Claudia Roach, Zheng Hou, Christophe L. M. J. Verlinde, Wim G. J. Hol, Erkang Fan

    The structure-based design of multivalent ligands offers an attractive strategy toward high affinity protein inhibitors. The spatial arrangement of the receptor-binding sites of cholera toxin, the causative agent of the severe diarrheal disease cholera and a member of the AB5 bacterial toxin family, provides the opportunity of designing branched multivalent ligands with 5-fold symmetry. Our modular synthesis enabled the construction of a family of complex ligands with five flexible arms each ending with a bivalent ligand. The largest of these ligands has a molecular weight of 10.6 kDa. These ligands are capable of simultaneously binding to two toxin B pentamer molecules with high affinity, thus blocking the receptor-binding process of cholera toxin. A more than million-fold improvement over the monovalent ligand in inhibitory power was achieved with the best branched decavalent ligand. This is better than the improvement observed earlier for the corresponding nonbranched pentavalent ligand. Dynamic light scattering studies demonstrate the formation of concentration-dependent unique 1:1 and 1:2 ligand/toxin complexes in solution with no sign of nonspecific aggregation. This is in complete agreement with a crystal structure of the branched multivalent ligand/toxin B pentamer complex solved at 1.45 Å resolution that shows the specific 1:2 ligand/toxin complex formation in the solid state. These results reiterate the power of the structure-based design of multivalent protein ligands as a general strategy for achieving high affinity and potent inhibition.